Drug Discovery

Can Russia's New mRNA Vaccine Revolutionize Cancer Treatment by 2025?
Research & Development Can Russia's New mRNA Vaccine Revolutionize Cancer Treatment by 2025?

The recent announcement by Russia regarding the development of a groundbreaking mRNA cancer vaccine represents a significant milestone in the global fight against cancer. Scheduled for free distribution in early 2025, this innovative vaccine has captured worldwide attention due to its potential to

Does 5-FU Fight Cancer by Targeting RNA Instead of DNA?
Research & Development Does 5-FU Fight Cancer by Targeting RNA Instead of DNA?

5-Fluorouracil (5-FU) has been a cornerstone in cancer treatment for decades, primarily believed to work by damaging DNA and preventing cancer cells from replicating. However, recent research suggests that 5-FU's primary mechanism of action may be through targeting RNA, particularly ribosomal

MilliporeSigma Acquires HUB Organoids, Advancing Drug Development
Biotech & Bioprocessing MilliporeSigma Acquires HUB Organoids, Advancing Drug Development

MilliporeSigma, the Life Science business of Merck KGaA in the U.S. and Canada, has announced a definitive agreement to acquire HUB Organoids Holding B.V. (HUB). This acquisition marks a significant step forward in enhancing their 2D and 3D cell culture portfolio with the innovative technology of

Could a Novel Drug Enhance Muscle Repair in Duchenne Muscular Dystrophy?
Research & Development Could a Novel Drug Enhance Muscle Repair in Duchenne Muscular Dystrophy?

A groundbreaking study led by Natasha Chang at McGill University has shown that a novel drug, K884, holds promise for treating Duchenne muscular dystrophy (DMD), a devastating genetic disorder characterized by severe muscle degeneration. Unlike conventional treatments, which primarily focus on

NICE Approves Neuraxpharm's Ublituximab for RRMS Treatment in the UK
Research & Development NICE Approves Neuraxpharm's Ublituximab for RRMS Treatment in the UK

The recent endorsement of Neuraxpharm's ublituximab (BRIUMVI®) by the National Institute for Health and Care Excellence (NICE) marks a significant step forward in the treatment of relapsing-remitting multiple sclerosis (RRMS). This approval is a notable accomplishment for the European

Why Is AbbVie Acquiring Nimble Therapeutics for Immune Drug Development?
Research & Development Why Is AbbVie Acquiring Nimble Therapeutics for Immune Drug Development?

AbbVie's recent acquisition of Nimble Therapeutics, a Roche spinout specializing in peptide-based oral drugs for immune diseases, represents a strategic move to enhance its already robust immunology pipeline. The $200 million deal is aimed at bolstering AbbVie's portfolio, particularly

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later